Financial Performance - The company's operating revenue for Q3 2022 was ¥454,473,519.21, representing a decrease of 5.09% compared to the same period last year[6] - Net profit attributable to shareholders for Q3 2022 was ¥16,906,408.94, an increase of 107.80% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,693,144.01, up 102.70% from the previous year[6] - Total operating revenue for the first three quarters of 2022 was CNY 1,314,938,470.37, a decrease of 1.3% compared to CNY 1,329,473,254.17 in the same period of 2021[33] - Net profit for the third quarter of 2022 was CNY 50,943,199.09, an increase of 34.8% compared to CNY 37,789,530.07 in the same quarter of 2021[37] - Earnings per share for the third quarter of 2022 were CNY 0.0272, up from CNY 0.0252 in the same period last year, indicating a growth of 7.9%[39] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,331,187,516.49, reflecting a 2.98% increase from the end of the previous year[8] - As of September 30, 2022, the company's total assets amounted to RMB 2,331,187,516.49, an increase from RMB 2,263,654,921.95 at the end of 2021[23] - Total liabilities as of September 30, 2022, were RMB 1,145,153,845.66, compared to RMB 1,093,564,451.21 at the end of 2021, marking an increase of about 4.7%[29] - The company reported a total current liabilities of RMB 1,125,531,262.02, an increase from RMB 1,073,941,867.57 at the end of 2021[29] - The company's total equity attributable to shareholders was CNY 1,419,638,543.69, showing an increase from CNY 1,405,829,828.65 in the previous reporting period[31] Cash Flow - Cash flow from operating activities for the year-to-date was ¥138,595,957.36, showing a 61.18% increase[8] - Cash flow from operating activities for the first three quarters of 2022 was CNY 1,510,958,131.72, an increase of 4.7% compared to CNY 1,442,652,067.22 in the same period of 2021[40] - The net cash flow from operating activities was $138,595,957.36, an increase of 61.1% compared to $85,989,575.12 in the previous period[42] - Total cash inflow from financing activities was $1,046,198,204.59, while cash outflow was $418,262,232.26, resulting in a net cash flow of $627,935,972.33[44] - The cash and cash equivalents at the end of the period amounted to $704,226,049.41, up from $612,186,953.28 at the beginning of the period, reflecting a net increase of $92,039,096.13[44] Inventory and Fixed Assets - The company's inventory decreased by 41.69% due to increased sales of products[15] - The company's fixed assets increased by 44.69% due to the transfer of newly constructed projects[15] - The company's inventory decreased significantly to RMB 53,949,614.07 from RMB 92,524,544.80, representing a decline of approximately 41.7%[27] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 61,854[16] - The largest shareholder, Wuhu Liantai Investment Management Center, held 10.06% of the shares, amounting to 180,509,529 shares[16] Financial Improvements - The company reported a financial expense of CNY -13,598,245.86, a significant improvement compared to CNY 12,431,574.02 in the same period last year[33] - The company experienced a credit impairment loss of CNY 70,229.58, compared to a loss of CNY -101,284.69 in the previous year, indicating a recovery trend[37] - The net cash flow from investment activities was -$31,556,862.23, an improvement from -$57,961,161.18 in the previous period[42] Other Information - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[22]
莲花健康(600186) - 2022 Q3 - 季度财报